CRDF Stock Forecast: Cardiff Oncology, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Cardiff Oncology, Inc. is $6. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 48 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Cardiff Oncology, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (95): Sales and profits are climbing, and climbing faster than before.
Value (15): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
CRDF stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on CRDF, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 15 Sept 2026 | HC Wainwright & Co. | Upgrade | Buy | $9.00 |
| 12 Aug 2026 | William Blair | Downgrade | Market Perform | — |
| 3 June 2026 | Craig-Hallum | Downgrade | Hold | $10 → $2.00 |
| 1 June 2026 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 1 June 2026 | TD Cowen | Downgrade | Hold | — |
| 25 Feb 2026 | Piper Sandler | Maintains | Overweight | — |
| 28 Jan 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 6 Aug 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 8 July 2025 | Ladenburg Thalmann | Initiates | Buy | — |
| 24 June 2025 | Jefferies | Initiates | Hold | — |
| 9 May 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 28 Feb 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 13 Dec 2024 | Piper Sandler | Maintains | Overweight | — |
| 8 Nov 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 6 Sept 2024 | Craig-Hallum | Initiates | Buy | — |
| 6 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 6 Mar 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 1 Mar 2024 | Piper Sandler | Maintains | Overweight | — |
| 11 Aug 2023 | HC Wainwright & Co. | Maintains | Buy | — |
| 8 Aug 2023 | HC Wainwright & Co. | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for CRDF.
This page is one stock. Monday covers all of them.
CRDF appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
CRDF vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Cardiff Oncology, Inc. returned −56.5% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
CRDF analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 121.1×
- Price / book
- 2.4×
- EV / EBITDA
- —
Cheaper than 3% of US stocks
Cheaper than 37% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −97.9%
- Return on assets
- −49.3%
- Dividend yield
- —
Higher than 14% of US stocks
Higher than 8% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Cardiff Oncology, Inc. has a market value of $69.2M and an enterprise value of $35.9M.
Revenue in the twelve months to 30 June 2026: $508K. The latest quarter shrank 14.0% year on year.
Net income over the same four quarters: −$40.1M, a −7884.1% net margin.
Free cash flow in the twelve months to 30 June 2026: −$40.9M.
Cardiff Oncology, Inc. employs 30 people — $17K of revenue per employee.
Data provided by Twelve Data
CRDF and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at CRDF’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Cardiff Oncology, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about CRDF
What is the CRDF stock price forecast for 2026-2027?
The median 12-month analyst price target for Cardiff Oncology, Inc. is $6, with estimates ranging from $1.2 to $9. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is CRDF stock a buy right now?
Of the 5 analysts covering Cardiff Oncology, Inc., 2 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cardiff Oncology, Inc. 48 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank CRDF?
As at 21 Nov 2026, Cardiff Oncology, Inc. ranks 48 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (95 of 100).
Will CRDF stock go up?
No one can know that. What the data says: the median 12-month target from 5 analysts is $6, and Ticker Nerd's factor model ranks Cardiff Oncology, Inc. 48 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the CRDF stock forecast for 2030?
No analyst covering Cardiff Oncology, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CRDF are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1.2 to $9 over the next 12 months.
How has CRDF stock performed over the past year?
Cardiff Oncology, Inc. returned -56.5% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Cardiff Oncology, Inc. do?
Cardiff Oncology Inc. is a clinical-stage biotechnology company focused on developing cancer therapies that target Polo-like Kinase 1 (PLK1), a validated oncology pathway involved in cell division. Its lead product candidate, onvansertib, is an oral and selective PLK1 inhibitor being studied in combination with standard-of-care treatments across multiple cancer types.
About Cardiff Oncology, Inc.
Cardiff Oncology Inc. is a clinical-stage biotechnology company focused on developing cancer therapies that target Polo-like Kinase 1 (PLK1), a validated oncology pathway involved in cell division. Its lead product candidate, onvansertib, is an oral and selective PLK1 inhibitor being studied in combination with standard-of-care treatments across multiple cancer types. The company’s current clinical programs center on difficult-to-treat solid tumors and hematologic malignancies, including colorectal cancer, prostate cancer, pancreatic cancer, lung cancer, and breast cancer. Cardiff Oncology’s work is aimed at addressing treatment resistance and improving the effectiveness of existing cancer regimens through combination approaches. Headquartered in San Diego, California, Cardiff Oncology operates as a focused oncology drug development company within the broader biotechnology sector.
CEO Dr. Mani Mohindru Ph.D. · 30 employees · United States · https://www.cardiffoncology.com